Chronic Fatigue Syndrome Clinical Trial
Official title:
A 3-day Course for Adults With Chronic Fatigue Syndrome/Myalgic Encephalopathy (CFS/ME): a Randomized Controlled Trial
NCT number | NCT05236465 |
Other study ID # | 394844 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | March 21, 2022 |
Est. completion date | April 1, 2026 |
Chronic fatigue syndrome/Myalgic encephalomyelitis (CFS/ME) can be a serious and disabling condition with a heavy symptom burden and low function. Work disability is common, and social life dramatically affected. CFS/ME is a challenging health problem as well as a societal problem. In recent years, a doubling of the number of patients with a CFS/ME diagnoses has been reported in Norway. The patient group represents a challenge for the health care system, the municipality, and the Norwegian Labour and Welfare Organization (NAV). According to new figures, the NAV pays 100 million Norwegian Kroner (NOK) each month in permanently incapacitated expenses for people with CFS/ME. Municipalities have expenses in form of care, rehabilitation and other measures. There is a lack of effective treatment for CFS/ME. Evidence-based knowledge is highly needed. If the 3-day course shows promising effects, this could have positive consequences for patients, relatives and health personnel, but also financially for the society and the municipality.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | April 1, 2026 |
Est. primary completion date | April 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - CFS/ME diagnosis based on the Canada Consensus Criteria. - At least 50% out of school/work. - Readiness to change (corresponding to the preparation phase in transtheoretical model) - Has given informed consent. Exclusion Criteria: - Assessed by a General Practitioner (GP): - Underlying physical illness or mental disorder that may explain the symptoms. - Suicide risk/previous suicide attempts. - Pregnancy. - Bedridden and in need of continuous care. - Insufficient Norwegian speaking or writing skills to participate in the 3-day course and fill out questionnaires. |
Country | Name | City | State |
---|---|---|---|
Norway | Department of Psychology, NTNU | Trondheim |
Lead Sponsor | Collaborator |
---|---|
Norwegian University of Science and Technology | Haukeland University Hospital, Lørenskog municipality, The Research Council of Norway, University of Bristol, University of Oslo |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Physical function | Measured through the Short Form Health Survey (SF-36), physical function, a scale that measures physical function with questions relating to ability to perform physical activity. The instrument contains 10 items with three options on each question. The score range is 0 -100, where 100 is equivalent to no disability. | 10 weeks after the 3-day course | |
Secondary | Fatigue | Measured through the Chalder Fatigue Questionnaire, an instrument that measures fatigue severity, both on mental and physical fatigue in the last month. The instrument contains 11 items with four different response options in each question. The scale ranges from 0-33, where higher score indicates greater fatigue. | 6 months after the 3-day course | |
Secondary | Pain on a daily basis | Measured through the Brief Pain Inventory, an instrument measuring pain and its allied aspects. The instrument contains 11 items with numeric rating from 0-10, where higher score indicates more severe pain. | 6 months after the 3-day course | |
Secondary | Post-Exertional Malaise | Measured through A Brief Questionnaire to Assess Post-Exertional Malaise, an instrument that measures symptoms after activity. The instrument contains 10 items, with options ranging from 0-4, where a higher score indicates more severity. | 6 months after the 3-day course | |
Secondary | Mental wellbeing | Measured trough the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS), an instrument that measures mental wellbeing. The instrument contains 14 items, with 5 response categories, summed to provide a single score. Higher score indicates better wellbeing. | 6 months after the 3-day course | |
Secondary | Overall improvement | Measured through the Patient Global Impression of Change (PGIC) with one single item that measures change in function, symptoms and quality of life. The instrument has seven possible options ranging from very much better to very much worse. | 6 months after the 3-day course | |
Secondary | Sick leave | Register data from the Norwegian Labour and Welfare Administration (NAV) on sick leave, benefits, diagnoses from 12 months before the 3-day course and 24 months after the 3-day course. | 24 months after the 3-day course |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05454683 -
Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
|
N/A | |
Completed |
NCT01686074 -
Motor Control in Chronic Fatigue Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT02075489 -
Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans
|
N/A | |
Completed |
NCT01651754 -
Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome
|
N/A | |
Completed |
NCT00540254 -
Behavioral Insomnia Therapy With Chronic Fatigue Syndrome
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00071162 -
Genetics of Fibromyalgia
|
N/A | |
Withdrawn |
NCT04870476 -
Feasibility and Acceptability of the Internet-delivered Treatment "One Step at the Time" for Bodily Distress Syndrome
|
N/A | |
Completed |
NCT05730660 -
Quercetin Phytosome® Chronic Fatigue Syndrome
|
N/A | |
Recruiting |
NCT04542161 -
Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
|
Phase 2 | |
Recruiting |
NCT03807973 -
Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.
|
Phase 1 | |
Recruiting |
NCT05719493 -
Effectiveness and Health Benefits of a Nutritional, Chronobiological and Physical Exercise Intervention in Fibromyalgia and Chronic Fatigue Syndrome (SYNCHRONIZE +)
|
N/A | |
Recruiting |
NCT05967052 -
Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation
|
Phase 2 | |
Terminated |
NCT01730495 -
Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome
|
Phase 2 | |
Completed |
NCT01156909 -
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome
|
Phase 2 | |
Completed |
NCT01650636 -
Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process
|
N/A | |
Completed |
NCT01046370 -
A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia
|
N/A | |
Completed |
NCT00100412 -
Hyporeactivity and Gulf War Illness
|
N/A | |
Recruiting |
NCT06128967 -
A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial
|
Phase 3 | |
Completed |
NCT02669212 -
Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health
|
N/A | |
Not yet recruiting |
NCT06011135 -
Exploring Worry in CFS/ME
|